• AKT inhibitor
• capivasertib based treatment
• capivasertib plus paclitaxel
• ipatasertib based treatment
• ipatasertib plus paclitaxel
• antibody–drug conjugate
• sacituzumab govitecan
• trastuzumab deruxtecan
• trastuzumab emtansine
• trastuzumab emtasine plus endocrine therapy
• aurora kinase inhibitors
• alisertib plus paclitaxel
• biguanide
• metformin
• celecoxib plus endocrine therapy
• chemotherapy
• non platinum-based chemotherapy
• microtubul inhibitor
• eribulin
• nucleoside analogues (pyrimidine/purine)
• capecitabine
• taxanes
• paclitaxel
• nab-paclitaxel
• paclitaxel followed by doxorubicin plus cyclophosphamide
• pegylated liposomal doxorubicin and cyclophosphamide
• Standard of Care (SoC)
• cyclin inhibitor
• abemaciclib based treatment
• abemaciclib plus aromatase inhibitor
• abemaciclib plus endocrine therapy
• abemaciclib plus fulvestrant
• dalpiciclib plus fulvestrant
• palbociclib based treatment
• palbociclib
• palbociclib plus endocrine therapy
• palbociclib plus fulvestrant
• palbociclib plus letrozole
• ribociclib based treatment
• ribociclib plus endocrine therapy
• ribociclib plus fulvestrant
• ribociclib plus letrozole
• endocrine therapy
• androgen deprivation therapy (ADT)
• abiraterone plus ADT
• abiraterone plus docetaxel plus ADT
• apalutamide plus ADT
• darolutamide plus doxetaxel plus ADT
• docetaxel plus ADT
• enzalutamide
• enzalutamide plus ADT
• gene alteration target therapy
• BRAF gene alteration targeted therapy
• BRAF inhibitor
• combined BRAF-MEK inhibitors
• trametinib plus dabrafenib
• KRAS gene alteration targeted therapy
• sotorasib
• MET gene alteration targeted therapy
• capmatinib
• NTRK gene alteration targeted therapy
• entrectinib
• larotrectinib
• RET gene alteration targeted therapy
• pralsetinib
• selpercatinib
• HDAC inhibitor
• entinostat plus exemestane
• tucidinostat based treatment
• tucidinostat plus exemestane
• HER inhibitor
• EGFR inhibitor
• afatinib based treatment
• afatinib plus vinorelbine
• HER2 inhibitor
• neratinib based treatment
• neratinib
• neratinib plus capecitabine
• pertuzumab based treatment
• pertuzumab plus trastuzumab
• pertuzumab plus trastuzumab plus docetaxel
• trastuzumab based treatment
• docetaxel plus carboplatin with trastuzumab followed by trastuzumab
• doxorubicin plus cyclophosphamide followed by docetaxel plus trastuzumab
• trastuzumab plus endocrine therapy
• trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel
• tucatinib based treatment
• tucatinib plus trastuzumab plus capecitabine
• TKI anti HER1/EGFR and HER2/neu
• lapatinib based treatment
• lapatinib
• lapatinib plus capecitabine
• lapatinib plus fulvestrant
• lapatinib plus letrozole
• lapatinib plus paclitaxel
• lapatinib plus trastuzumab
• lapatinib plus trastuzumab plus paclitaxel
• IGF-1R inhibitors
• dalotuzumab plus ridaforolimus plus exemestane
• ganitumab plus endocrine therapy
• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab alone
• Ipilimumab (10 mg/kg)
• ipilimumab plus gp100
• ipilimumab plus SoC
• tremelimumab
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus bevacizumab
• atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
• atezolizumab plus cabozantinib
• atezolizumab plus carboplatin plus nab-paclitaxel
• atezolizumab plus carboplatin plus paclitaxel
• atezolizumab plus cometinib
• atezolizumab plus FOLFOXIRI plus bevacizumab
• atezolizumab plus nab-paclitaxel
• atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide
• atezolizumab plus paclitaxel
• atezolizumab plus pemetrexed and platin
• atezolizumab plus SoC
• avelumab based treatment
• avelumab alone
• avelumab plus axitinib
• avelumab plus pegylated liposomal doxorubicin
• avelumab plus SoC
• camrelizumab based treatment
• camrelizumab alone
• cemiplimab
• dostarlimab based treatment
• dostarlimab plus soC
• durvalumab based treatment
• durvalumab alone
• durvalumab plus bevacizumab
• durvalumab plus etoposide and platin
• durvalumab plus olaparib plus SoC
• durvalumab plus osimertinib
• durvalumab plus SoC
• nivolumab based treatment
• nivolumab alone
• nivolumab plus cabozantinib
• nivolumab plus SoC
• nivolumab followed by ipilimumab
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab (10mg/kg)
• pembrolizumab (10mg/kg) 2 weeks
• pembrolizumab (2mg/kg)
• pembrolizumab and pemetrexed plus platin
• pembrolizumab plus 5FU plus platin
• pembrolizumab plus axitinib
• pembrolizumab plus lenalidomide and dexamethasone
• pembrolizumab plus lenvatinib
• pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide
• pembrolizumab plus pomalidomide and dexamethasone
• pembrolizumab plus SoC
• sintilimab based treatment
• sintilimab
• sintillimab plus SoC
• Tislelizumab
• toripalimab
• Immune checkpoint association
• durvalumab plus tremelimumab
• durvalumab plus tremelimumab plus SoC
• nivolumab plus ipilimumab
• nivolumab plus ipilimumab plus SoC
• pembrolizumab plus ipilimumab
• relatlimab plus nivolumab
• Immunostimulant
• vaccine
• AE37 vaccine plus GM-CSF
• GP2 vaccine plus GM-CSF
• OBI-822/OBI-821 plus cyclophosphamide
• inetetamab plus vinorelbine
• mTOR inhibitors
• everolimus
• lenvatinib plus everolimus
• sapanisertib plus fulvestrant
• phosphoinositide 3-kinase (PI3K) inhibitor
• alpelisib based treatment
• alpelisib plus fulvestrant
• alpelisib plus letrozole
• buparlisib based treatment
• buparlisib plus fulvestrant
• buparlisib plus letrozole
• taselisib based treatment
• taselisib plus letrozole
• poly ADP-ribose polymerase (PARP) inhibitor
• niraparib
• olaparib
• rucaparib
• talazoparib
• veliparib plus paclitaxel plus carboplatin
• target therapy
• margetuximab based treatment
• margetuximab plus chemotherapy
• multikinase inhibitor
• nintedanib
• VEGF(R) inhibitor
• bevacizumab based treatment
• bevacizumab
• bevacizumab plus trastuzumab plus docetaxel
• cediranib plus fulvestrant
• lenvatinib
• lenvatinib in association